Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04443088 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
A Phase 1 study of Cancer and Solid Tumor, Adult, sponsored by Shenzhen Ionova Life Sciences Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 3
- Study locations
NCT04443088: Recruiting Phase 1 study of Cancer and Solid Tumor, Adult, sponsored by Shenzhen Ionova Life Sciences Co..
NCT04443088 is a Phase 1 study of Cancer and Solid Tumor, Adult that is actively recruiting participants, run by Shenzhen Ionova Life Sciences Co.. The registered enrollment target is 78 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04443088, a Phase 1 study of Cancer and Solid Tumor, Adult, is actively recruiting participants, sponsored by Shenzhen Ionova Life Sciences Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.
Primary Outcome
To evaluate dose limiting toxicities (DLTs) of INV-1120 in patients with advanced cancer and to establish a recommended Phase 2 dose (RP2D)
Conditions Studied
Interventions
- COMBINATION_PRODUCT Pembrolizumab
- DRUG INV-1120
Study Locations (3)
Texas
- START - San Antonio
- UT Health - San Antonio
Indiana
- Horizon Oncology Research, LLC, - Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2020-06-26 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT04443088 shows while recruiting
NCT04443088 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04443088 reports a single indexed study location in Texas, Indiana.
Frequently Asked Questions
What is clinical trial NCT04443088 about?
NCT04443088 is a clinical study titled "An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors". Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed ...
What is the current status of trial NCT04443088?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2020-06-26. Estimated completion is 2026-12-31.
What conditions does trial NCT04443088 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor, Adult, Tumor, Solid, Cancer Metastatic, Solid Carcinoma.
What interventions are being tested in trial NCT04443088?
The interventions under investigation include: Pembrolizumab (COMBINATION_PRODUCT), INV-1120 (DRUG).
Who is sponsoring clinical trial NCT04443088?
This trial is sponsored by Shenzhen Ionova Life Sciences Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04443088 being conducted?
This trial has 3 study locations across Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04443088's enrollment target sits among peer trials
78 362nd of 615 higher than 253 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI